TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 39.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 46,127 shares of the biopharmaceutical company's stock after selling 30,413 shares during the period. Jackson Creek Investment Advisors LLC's holdings in TG Therapeutics were worth $1,388,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC acquired a new position in TG Therapeutics in the 4th quarter valued at $245,000. Castellan Group purchased a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $8,539,000. Oppenheimer & Co. Inc. acquired a new stake in shares of TG Therapeutics in the 3rd quarter worth approximately $759,000. Segall Bryant & Hamill LLC purchased a new position in TG Therapeutics in the 3rd quarter valued at approximately $1,225,000. Finally, Barclays PLC increased its position in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after buying an additional 158,323 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.50% of the stock is owned by corporate insiders.

Remove Ads

TG Therapeutics Trading Down 4.3 %

TGTX traded down $1.68 during trading on Tuesday, hitting $37.55. 3,801,786 shares of the company's stock were exchanged, compared to its average volume of 2,638,415. The stock has a 50 day moving average price of $31.23 and a 200 day moving average price of $28.67. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $40.31. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market cap of $5.90 billion, a P/E ratio of -375.46 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. Finally, HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.